X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Monday: CMS withdraws Part B demo, takes positive step forward on CMMI

By Nicole Longo  |    October 30, 2017
In case you missed it, earlier this month, the Center for Medicare & Medicaid Services formally withdrew a controversial proposal that would have had a detrimental impact on patient access to...   Read More

Disease modifying therapies for the management of multiple sclerosis save money and improve patient outcomes

By Samantha Dougherty  |    October 24, 2017
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study comparing the effectiveness of oral and...   Read More

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

By Nicole Longo  |    October 20, 2017
Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have...   Read More

The Washington Post retracts PhRMA claim in opioid story

By Holly Campbell  |    October 18, 2017
Earlier this week, The Washington Post falsely claimed that the PhRMA supported the Ensuring Patient Access and Effective Drug Enforcement Act of 2016 and spent $40 million advocating for its...   Read More

Excerpts from testimony by PhRMA’s Lori Reilly

By Holly Campbell  |    October 17, 2017
Today, Lori Reilly, executive vice president for policy, research and membership at the Pharmaceutical Research and Manufacturers of America (PhRMA), testified at the U.S. Senate Committee on...   Read More

How much are hospitals marking up the price of medicines? The answer may surprise you.

By Robert Zirkelbach  |    October 17, 2017
Hospitals mark up medicine prices, on average, nearly 500 percent, according to a new analysis from the Moran Company that was commissioned by the Pharmaceutical Research and Manufacturers of...   Read More

Medicare Monday: Open enrollment is here again

By Nicole Longo  |    October 16, 2017
It’s that time of year again: Medicare open enrollment! As of Sunday, October 15, newly qualified patients and current Medicare beneficiaries can review their coverage options and select their...   Read More

PhRMA response to Washington Post and 60 Minutes stories

By Robert Zirkelbach  |    October 16, 2017
The opioid epidemic confronting America is a growing public health crisis from which none of us are immune. Its impact is felt by families across the country, in small towns and large cities,...   Read More

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

By Holly Campbell  |    October 12, 2017
PhRMA president and CEO Stephen J. Ubl joined Fox Business’ Maria Bartiromo on “Mornings with Maria” today to discuss bold steps the biopharmaceutical industry has taken in the last few months as...   Read More

PhRMA, member companies and NIH create public-private partnership for immuno-oncology

By Andrew Powaleny  |    October 12, 2017
The rapid pace of scientific advances has helped usher in a new era of medicine for cancer patients over the last decade. This morning, the National Institutes of Health (NIH) took a significant...   Read More

2017 Research & Hope Awards honor innovators in mental health

By Hannah Mooney  |    October 10, 2017
Mental health disorders are a heavy human and economic burden in the United States. More than 40 million people across the country are impacted by mental illness, and it’s estimated that in any...   Read More

PhRMA Foundation recognizes inaugural Challenge Award recipients

By Eileen Cannon  |    October 6, 2017
Last month, the PhRMA Foundation announced the recipients of the inaugural Challenge Awards at Morning Consult. These awards recognize the best and the brightest that are identifying...   Read More

The next five years of PDUFA VI: Driving the availability of innovative treatments for patients

By Bill Chin, M.D.  |    October 2, 2017
Yesterday, October 1, marked the first day of implementation for PDUFA VI, the next iteration of the Prescription Drug User Fee Act (PDUFA) and one of the best tools that the U.S. Food and Drug...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates